Application of Remimazolam, Dexmedetomidine, and Esketamine in Pediatric Preoperative Sedation
NCT ID: NCT07050212
Last Updated: 2025-07-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
150 participants
INTERVENTIONAL
2025-04-01
2026-03-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Determination of ED50 and ED95 With Clinical Efficacy of Intranasal Dexmedetomidine Combined With Esketamine for Preoperative Sedation in Pediatric General Anesthesia
NCT06853431
Clinical Study of Oral Midazolam Combined With Esketamine Administered Intranasally for Pediatric Preoperative Sedation
NCT05925283
Combination With Intranasal Dexmedetomidine and Oral Midazolam for Premedication in Pediatric Patients
NCT04135014
Intranasal Remimazolam for Premedication in Pediatric Patient
NCT04720963
Effect of Esketamine on 95% Induction Dose of Remimazolam
NCT06303037
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Remimazolam group: Remimazolam is administered intravenously at a dose of 0.3 mg/kg
Remimazolam is administered intravenously at a dose of 0.3 mg/kg
remimazolam group
remimazolam is administered intravenously at a dose of 0.3 mg/kg
dexmedetomidine group: dexmedetomidine is administered intravenously at a dose of 1 μg/kg
dexmedetomidine is administered intravenously at a dose of 1 μg/kg
dexmedetomidine group
dexmedetomidine is administered intravenously at a dose of 1 μg/kg
esketamine group: esketamine is administered intravenously at a dose of 0.5 mg/kg
esketamine is administered intravenously at a dose of 0.5 mg/kg
esketamine group
esketamine is administered intravenously at a dose of 0.5 mg/kg
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
remimazolam group
remimazolam is administered intravenously at a dose of 0.3 mg/kg
dexmedetomidine group
dexmedetomidine is administered intravenously at a dose of 1 μg/kg
esketamine group
esketamine is administered intravenously at a dose of 0.5 mg/kg
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. the American Society of Anesthesiologists (ASA) physical status of Class I
3. scheduled for adenotonsillectomy under general anesthesia, will be included.
Exclusion Criteria
2. airway obstruction or deformity, history of mental illness
3. electrocardiogram indicating bradycardia
4. history of cardiac disease
2 Years
5 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Maternal and Child Health Hospital of Hubei Province
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Li Na
Deputy Chief Physician
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Na Li NaLi, MD
Role: PRINCIPAL_INVESTIGATOR
Maternal and Child Health Hospital of Hubei Province
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Maternal and Child Health Hospital of Hubei Province
Wuhan, Hubei, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MCHH_013
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.